

CERTOLIZUMAB

2007

PRECiSE I

RCT / Certolizumab pegol 400mg SC vs placebo / Mod-Severe CD/ Induction of remission

Conclusion:

In mod-severe CD, induction & maintenance therapy with certolizumab pegol was associated with a modest improvement in response rates, as compared with placebo, but with no significant improvement in remission rates.

2007

PRECiSE II

RCT / Certolizumab pegol 400mg SC vs placebo / Mod-Severe CD/ Maintenance

Conclusion:

Patients with mod-severe CD who responded to induction therapy with certolizumab were more likely to maintain response & remission at w26 with continued certolizumab than with placebo.

2010

PRECiSE III

OLE Certolizumab pegol 400mg SC vs placebo / Mod-Severe CD/ Maintenance up to 18 months

Conclusion:

Certolizumab pegol effectively maintains remission of CD for up to 18 months. Continuous therapy is more effective than interrupted therapy.

2011

WELCOME

RCT/ Certolizumab pegol in secondary failure to infliximab / CD / Induction of remission

Conclusion:

Response to OL induction therapy with certolizumab pegol was achieved by 62% of patients with moderate to severely CD and secondary failure to infliximab.